Efectos de fostamatinib (R788), un inhibidor oral de la tirosina quinasa esplénica, en la calidad de vida relacionada con la salud en pacientes con artritis reumatoide: análisis de resultados reportados por los pacientes de un estudio aleatorizado, doble ciego, controlado con placebo
The Journal of Rheumatology 2013; 40(3):369-78
This phase 2 clinical trial assessed the influence of fostamatinib on patient reported outcomes (PROs) in 457 patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). Patients received either placebo or fostamatinib 100 mg twice daily or 150 mg once daily (1:1:1) for 24 weeks in addition to their baseline MTX. Patients taking fostamatinib 100 mg twice daily had statistically significant improvements in health-related quality of life scores for pain, patien...